Faculty Profile

Daniel Olson
Section of Hematology / Oncology
Assistant Professor of Medicine
Referring Physician Access Line: 1-877-DOM-2730

Academic Interests

Dr. Olson’s research centers around improving the efficacy and safety of immunotherapy. This includes a research focus on investigator-sponsored trials targeting mechanisms of resistance to PD-1 antibody therapy. He also has a research interest in improving the management of immune-related adverse events (irAE) through translational work characterizing irAE mechanisms. Dr. Olson will work both in the Melanoma and Developmental Therapeutics programs. Within the DT program, he will focus on trials targeting mechanisms of immunotherapy resistance, and to help expand the use of cell therapy approaches in solid tumors.

Clinical Interests

Melanoma and cutaneous oncology, early-phase immunotherapy trials, immune-related adverse events


  • Olson DJ, Eroglu Z, Brockstein B, et al. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. Published online May 4, 2021:JCO2100079.
  • Luke JJ, Olson DJ, Allred JB, et al. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res. 2020;26(4):804-811.
  • Olson DJ, Rajagopal P, Tjota MY, Venkataraman G, Luke JJ, Gajewski TF. A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab. J Immunother Cancer. 2020;8(1). doi:10.1136/jitc-2019-000380
  • Olson DJ, Luke JJ. Improving therapy in metastatic uveal melanoma by understanding prior failures. Oncoscience. 2020;7(5-6):40-43.
  • Olson DJ, Luke JJ. The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development. Immunotherapy. 2019;11(3):155-159.


  • MD, 2014, Rush Medical College,
  • Residency, 2017, McGaw Medical Center of Northwestern University, Internal Medicine
  • Fellowship, 2020, The University of Chicago, Pritzker School of Medicine, Hematology and Oncology
  • Fellowship, 2020, The University of Chicago Pritzker School of Medicine, Clinical Pharmacology and Pharmacogenomics